Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bioventus Inc.BVS · Entity 4996 | Director | June 02, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bioventus Inc.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 43,982 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Exercise / conversion · Acquired 32,282 · Balance 43,982 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-02 · Exercise / conversion · Disposed 32,282 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2: The RSUs vested on June 2, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 25,146 |
Reported balance
After 2026-06-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-03 · Grant · Acquired 25,146 · Balance 25,146 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2: The RSUs vested on June 2, 2026.
F3: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 4, 2026 20:46 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 25,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001679773-26-000006 · wk-form4_1780605960.xml · derivative · entry 3 Cowdy Philip G. · CIK 0001679773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,146 Underlying: Class A Common Stock · 25,146 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:46 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 32,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001679773-26-000006 · wk-form4_1780605960.xml · derivative · entry 2 Cowdy Philip G. · CIK 0001679773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 32,282 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 2, 2026. F2 · derivative.expiration_date: The RSUs vested on June 2, 2026. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:46 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 32,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001679773-26-000006 · wk-form4_1780605960.xml · nonDerivative · entry 1 Cowdy Philip G. · CIK 0001679773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 01:29 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 32,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000303 · wk-form4_1749086974.xml · derivative · entry 2 Cowdy Philip G. · CIK 0001679773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,282 Underlying: Class A Common Stock · 32,282 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F2 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| April 01, 2022 Filed Apr 6, 2022 01:14 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 2,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-013962 · doc4.xml · derivative · entry 2 Cowdy Philip G. · CIK 0001679773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 2,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on April 1, 2022. F2 · derivative.expiration_date: The RSUs vested on April 1, 2022. Read SEC document |
| April 01, 2022 Filed Apr 6, 2022 01:14 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 2,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-013962 · doc4.xml · nonDerivative · entry 1 Cowdy Philip G. · CIK 0001679773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 02:15 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-006535 · doc4.xml · derivative · entry 2 Cowdy Philip G. · CIK 0001679773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 9,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vested on February 11, 2022. F2 · derivative.expiration_date: The restricted stock units vested on February 11, 2022. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 02:15 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 9,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-006535 · doc4.xml · nonDerivative · entry 1 Cowdy Philip G. · CIK 0001679773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:31 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 2,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-014833 · doc4.xml · derivative · entry 1 Cowdy Philip G. · CIK 0001679773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,700 Underlying: Class A Common Stock · 2,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest on April 1, 2022 and have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest on April 1, 2022 and have no expiration date. Read SEC document |
| April 01, 2021 Filed Apr 14, 2026 22:19 UTC Amendment | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 2,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001679773-26-000004 · wk-form4a_1776205186.xml · derivative · entry 1 Cowdy Philip G. · CIK 0001679773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 2,700 shares Expires not disclosed F1 · security: On April 5, 2021, the Issuer inadvertently filed a Form 4 reporting a grant of restricted stock units that were not accepted by the Reporting Person. As of April 1, 2021, the Reporting Person held no non-derivative or derivative securities of the Issuer. F2 · derivative.exercise_price: None. F2 · derivative.exercise_date: None. F2 · derivative.expiration_date: None. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 23:12 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-006748 · doc4.xml · derivative · entry 1 Cowdy Philip G. · CIK 0001679773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Class A Common Stock · 9,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest on February 11, 2022. F2 · derivative.expiration_date: The restricted stock units vest on February 11, 2022. Read SEC document |
| February 11, 2021 Filed Apr 14, 2026 22:19 UTC Amendment | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001679773-26-000003 · wk-form4a_1776205165.xml · derivative · entry 1 Cowdy Philip G. · CIK 0001679773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 9,000 shares Expires not disclosed F1 · security: On February 16, 2021, the Issuer inadvertently filed a Form 4 reporting a grant of restricted stock units that were not accepted by the Reporting Person. As of February 11, 2021, the Reporting Person held no non-derivative or derivative securities of the Issuer. F2 · derivative.exercise_price: None. F2 · derivative.exercise_date: None. F2 · derivative.expiration_date: None. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.